Search results

...Guilera C, Jové M, Naudí A, Ferrer I, Pamplona R, Serrano M, Portero-Otín M, Beal MF, Fourcade S, Pujol A (2015) Activation of sirtuin 1 as therapy for ...Guilera C, Jove M, Naudi A, Ferrer I, Pamplona R, Serrano M, Portero-Otin M, Beal MF, Fourcade S, Pujol A

...P, Dierssen M, Ferrer I, Villarroya F, Pamplona R, Vaquero A, Portero-Otín M, Pujol A (2017) Loss of SIRT2 leads to axonal degeneration and locomotor di ...P, Dierssen M, Ferrer I, Villarroya F, Pamplona R, Vaquero A, Portero-Otín M, Pujol A

...s D, Boada J, Martínez J, Ferrer I, Pamplona R, Villarroya F, Portero-Otín M, Fourcade S, Pujol A (2013) Impaired mitochondrial oxidative phosphorylatio ...s D, Boada J, Martinez J, Ferrer I, Pamplona R, Villarroya F, Portero-Otin M, Fourcade S, Pujol A

...res P, Ayala V, Moiseeva V, Povedano M, Ferrer I, Pamplona R, Portero-Otin M, Boada J (2016) Early and gender-specific differences in spinal cord mitoch ...res P, Ayala V, Moiseeva V, Povedano M, Ferrer I, Pamplona R, Portero-Otin M, Boada J

...o MP, Motilva MJ, Nonaka T, Hasegawa M, Ferrer I, Pamplona R, Portero-Otín M (2016) Interplay between TDP-43 and docosahexaenoic acid-related processes ...o MP, Motilva MJ, Nonaka T, Hasegawa M, Ferrer I, Pamplona R, Portero-Otin M

...Martin-Gari M, Canudes M, Peralta S, Moga MJ, Boada J, Pamplona R, Portero M, Brieva L, Gonzalo H ...Canudes M(2), Peralta S(1), Moga MJ(3), Boada J(2), Pamplona R(2), Portero M(2), Brieva L(3), Gonzalo H(1,3)

|authors=Wuest RCI, Knottnerus SJG, Mengarelli I, Portero V, Ijlst L, Bleeker JC, Ferdinandusse S, Wanders RJA, Wijburg FA, Visser G, ...th (1) 50 μM resveratrol to increase mitochondrial biogenesis, or (2) 100 μM etomoxir – a powerful inhibitor of the rate controlling enzyme carnitinep

|authors=Gomez Rodriguez A, Sanchez-Roman I, Naudi A, Lopez-Torres M, Pamplona R, Barja G # Sanchez-Roman I, Gomez J, Naudi A, Ayala V, Portero-Otín M, Lopez-Torres M, Pamplona R, Barja G (2010) The beta-blocker atenolol lowers the longevity-